New drug combo aims to control rare kidney cancer

NCT ID NCT06053658

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing whether combining two drugs, tivozanib and nivolumab, can help control advanced non-clear cell kidney cancer. About 48 adults with this rare cancer type will receive the drugs to see how safe they are and whether they shrink or slow tumor growth. The study is currently recruiting participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tivozanib and nivolumab
What this could lead to: If successful, this combination could offer a new treatment option for people with a rare type of kidney cancer that is hard to treat.
What could go wrong: This is a small, early-phase trial (Phase 2) with only 48 participants. The drugs may cause side effects, and it is not yet known if the combination will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
City of Hope
RECRUITING

Irvine, California, 92618, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.